TD Cowen raises Ascendis Pharma stock price target on revenue beat
TD Cowen raised its price target for Ascendis Pharma (ASND) to $352, citing strong Q3 revenue beats across its products. Revenue grew 86% YoY with a 92% gross margin. The company reaffirmed long-term revenue targets of €5B by 2030 and €10B by 2035. ASND stock trades near its 52-week high at $266.31. Other analysts also raised targets and maintained positive ratings.
How this was made
The 30-second read
Why it matters
The earnings beat and target upgrades create a bullish catalyst, but the stock remains near its 52‑week high, suggesting limited upside room.
Market read
Earnings beat and analyst upgrades provide a fresh, material catalyst for ASND, offering a medium‑term buying opportunity.
What to watch
Potential regulatory or clinical trial setbacks could offset the short‑term earnings momentum.
Background
Ascendis Pharma (NASDAQ:ASND) reported Q3 2026 results that beat consensus, prompting several analysts to raise price targets.
Ticker impact
Q3 2026 earnings beat estimates and multiple analysts raised price targets, indicating fresh positive fundamentals.
likely upward pressure as the market prices in the earnings beat and higher targets
Earnings beat, revenue growth, and raised price targets from TD Cowen, Wells Fargo and Raymond James provide a concrete catalyst for buying interest.
Market effects
Biotech and rare‑disease sector may see broader optimism from the earnings beat.
U.S. biotech investors likely to react positively; European markets less affected.
Limited to investors tracking biotech earnings; no macro‑level impact.
Counterpoint
The stock may already be priced in; further upside could be limited if guidance falls short of long‑term targets.
Key entities
- AnalystTD Cowen
Raised price target to $352 and maintained Buy rating.
- AnalystWells Fargo
Raised price target to $330, maintaining Overweight.
- AnalystRaymond James
Reiterated Outperform rating after earnings beat.


